Fibrosis severity and mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex in HCV-infected patients

Arab Journal of Gastroenterology

Volumn 12, Issue 2, 2011, Pages 68-73

  El Saadany, Sherif A ^a   Ziada, Dina H ^a   Farrag, Wael ^a   Hazaa, Sahar ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

HCV; Mannan binding lectin (MBL); MASP 1; MBL associated serine protease 1

Indexed keywords

MANNAN BINDING LECTIN; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE;

ADULT; ARTICLE; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MANNOSE-BINDING LECTIN; MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES; MIDDLE AGED; RNA, VIRAL; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 79959278029     PISSN: 16871979     EISSN: 20902387     Source Type: Journal    
DOI: 10.1016/j.ajg.2011.04.005     Document Type: Article

References (38)

1. Ye L., Wang X., Wang S., et al. CD56+ T cells inhibit hepatitis C virus replication in human hepatocytes. Hepatology 2009, 49(3):753-762.
2. Poordad F.F., Flamm S.L. Virological relapse in chronic hepatitis C. Antivir Ther 2009, 14(3):303-313.
3. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22(6):696-699.
4. Knodell R.G., Ishak K.G., Black W.C., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1(5):431-435.
5. Lanford R.E., Guerra B., Chavez D., et al. Cross-genotype immunity to hepatitis C virus. J Virol 2004, 78(3):1575-1581.
6. Kawasaki T. Structure and biology of mannan-binding protein, MBP, an important component of innate immunity. Biochim Biophys Acta 1999, 1473(1):186-195.
7. Larsen F., Madsen H.O., Sim R.B., et al. Disease-associated mutations in human mannose-binding lectin compromise oligomerization and activity of the final protein. J Biol Chem 2004, 279(20):21302-213011.
8. Butler G.S., Sim D., Tam E., et al. Mannose-Binding Lectin (MBL) mutants are susceptible to matrix metalloproteinase proteolysis: potential role in human MBL deficiency. J Biol Chem 2002, 277(20):17511-17519.
9. Chong W.P., To Y.F., Ip W.K., et al. Mannose-binding lectin in chronic hepatitis B virus infection. Hepatology 2005, 42(5):1037-1045.
10. Matsushita M., Hijikata M., Ohta Y., et al. Hepatitis C virus infection and mutations of Mannose-Binding Lectin gene MBL. Arch Virol 1998, 143(4):645-651.
11. Sasaki K., Tsutsumi A., Wakamiya N., et al. Mannose-binding lectin polymorphisms in patients with hepatitis C virus infection. Scand J Gastroenterol 2000, 35(9):960-965.
12. Kilpatrick D.C., Delahooke T.E., Koch C., et al. Mannan-binding lectin and hepatitis C infection. Clin Exp Immunol 2003, 132(1):92-95.
13. Dahl M.R., Thiel S., Matsushita M., et al. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity 2001, 15(1):127-135.
14. Gadjeva M, Thiel S, Jensenius JC. Assays for the mannan-binding lectin pathway. Curr Protocols Immunol 2003:13.6.1-8.
15. Ambrus G., Gal P., Kojima M., et al. Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: a study on recombinant catalytic fragments. J Immunol 2003, 170(3):1374-1382.
16. Presanis J.S., Hajela K., Ambrus G., et al. Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Mol Immunol 2004, 40(13):921-929.
17. Corpechot C., Barbu V., Wendum D., et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002, 35(5):1010-1021.
18. Neubauer K., Knittel T., Armbrust T., et al. Accumulation and cellular localization of fibrinogen/fibrin during short-term and long-term rat liver injury. Gastroenterology 1995, 108(4):1124-1135.
19. Bouwman L.H., Roos A., Terpstra O.T., et al. Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterology 2005, 129(2):408-414.
20. Berg T., Muller A.R., Platz K.P., et al. Dynamics of GB virus C viremia early after orthotopic liver transplantation indicates extrahepatic tissues as the predominant site of GB virus C replication. Hepatology 1999, 29(1):245-249.
21. Arnold J.N., Radcliffe C.M., Wormald M.R., et al. The glycosylation of human serum IgD and IgE and the accessibility of identified oligomannose structures for interaction with mannan-binding lectin. J Immunol 2004, 173(11):6831-6840.
22. Petersen S.V., Thiel S., Jensen L., et al. An assay for the mannan-binding lectin pathway of complement activation. J Immunol Methods 2001, 257(1-2):107-116.
23. Grasso A., Malfatti F., Leo P.D., et al. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009, 51(6):984-990.
24. Grakoui A. Hepatitis C virus infection: how does the host respond?. Minerva Gastroenterol Dietol 2004, 50(1):21-28.
25. Puoti C. HCV carriers with persistently normal ALT levels: not too much healthy, not true patients. Rom J Gastroenterol 2004, 13(4):329-332.
26. Rumi M.G., De Filippi F., Donato M.F., et al. Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough. J Viral Hepat 2002, 9(1):71-74.
27. Kanzler S., Baumann M., Schirmacher P., et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat 2001, 8(6):430-437.
28. Datz C., Cramp M., Haas T., et al. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut 1999, 44(4):563-567.
29. Alves Pedroso M.L., Boldt A.B.W., Pereira Ferrari L., et al. Mannan-binding lectin MBL2 gene polymorphism in chronic hepatitis C: association with the severity of liver fibrosis and response to interferon therapy. Clin Exp Immunol 2008, 152(2):258-264.
30. Marra F., DeFranco R., Grappone C., et al. Expression of the thrombin receptor in human liver: up-regulation during acute and chronic injury. Hepatology 1998, 27(2):462-471.
31. Papatheodoridis G.V., Papakonstantinou E., Andrioti E., et al. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 2003, 52(3):404-409.
32. Wright M., Goldin R., Hellier S., et al. Factor V leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003, 52(8):1206-1210.
33. Dunn D.L., Simmons R.L. Fibrin in peritonitis. III. The mechanism of bacterial trapping by polymerizing fibrin. Surgery 1982, 92(3):513-519.
34. Hurst T.J., Wilton J.M. Phagocytosis of porphyromonas gingivalis and prevotella intermedia by human polymorphonuclear leukocytes in clots formed from human plasma or purified fibrinogen. J Periodontal Res 1992, 27(2):111-118.
35. Szaba F.M., Smiley S.T. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 2002, 99(3):1053-1059.
36. Hajela K., Kojima M., Ambrus G., et al. The biological functions of MBL-associated serine proteases (MASPs). Immunobiology 2002, 205(4-5):467-475.
37. Senior R.M., Skogen W.F., Griffin G.L., et al. Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J Clin Invest 1986, 77(3):1014-1019.
38. Mayilyan K.R., Presanis J.S., Arnold J.N., et al. Heterogeneity of MBL-MASP complexes. Mol Immunol 2006, 43(8):1286-1292.